Stereotactic body radiotherapy 'on the rise' for HCC

Data from 10 Australian centres provides a snapshot of diverse practice in adoption of the emerging therapy

Stereotactic body radiation therapy is being increasingly used to treat hepatocellular carcinoma in Australia, but patient selection and dosing schedules vary widely, radiation oncologists say.


Their study shows that the emerging ablative therapy is being chosen first-line, for salvage after cancer recurrence, and as palliative therapy in patients with a range of tumour sizes and stages.

Stereotactic body radiation therapy (SBRT) was listed as an option for optimising local tumour control in 2020